Results 211 to 220 of about 547,226 (312)

Expectations and Reality: The Lived Experiences of Australians With Psychosocial Disability Within the NDIS

open access: yesAustralian Journal of Social Issues, EarlyView.
ABSTRACT While Australia's National Disability Insurance Scheme (NDIS) was founded on principles of choice and control, for people with significant mental health challenges (what the NDIS calls ‘psychosocial disability’) these ideals often remain elusive. Support systems continue to be fractured and in the context of ongoing policy reforms, it is vital
Joel Hollier, Jennifer Smith‐Merry
wiley   +1 more source

Temporal changes in occupational risks of COVID-19 hospitalisation in Germany, 2020-2021: a case-cohort study. [PDF]

open access: yesBMJ Public Health
Romero Starke K   +8 more
europepmc   +1 more source

Conceptual Approaches to Improving the Functioning of Non-state Social Insurance Institutions in Ukraine

open access: yesEconomics & Sociology, 2018
Mykhaylo Malyovanyi   +2 more
openaire   +2 more sources

Healthcare Resource Utilization and Cost After Temperature‐Controlled Radiofrequency Treatment of Nasal Airway Obstruction: A Real‐World Longitudinal Claims Analysis

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Nasal airway obstruction (NAO) is prevalent with substantial health and quality of life burdens. Nasal valve collapse (NVC) is one structural cause of NAO. Temperature‐controlled radiofrequency (TCRF) nasal valve remodeling offers an alternative to invasive surgery.
David W. Kennedy   +7 more
wiley   +1 more source

Screening for Social Determinants of Health in Patients With Systemic Lupus Erythematosus: A Point-of-Care Feasibility Study. [PDF]

open access: yesArthritis Care Res (Hoboken)
Lim SS   +11 more
europepmc   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy